Given that (1) 11C-beta-CFT is particularly selective to the DAT (compared to other monoamine transporters)30 and (2) dopaminergic axon terminals have been found in the orbitofrontal cortex and the amygdala31, Ouchi and co-workers assumed that the reduction of the 11C-beta-CFT binding potential observed in their study indicates loss of dopaminergic axon terminals in the orbitofrontal cortex and the amygdala in PD. This evidence concerns the gene SLC6A3 and Parkinson disease.